Literature DB >> 19605943

No association of three GRIN2B polymorphisms with lithium response in bipolar patients.

Aleksandra Szczepankiewicz1, Maria Skibińska, Aleksandra Suwalska, Joanna Hauser, Janusz K Rybakowski.   

Abstract

We investigated three polymorphisms in the NMDA receptor 2B subunit gene (GRIN2B) as a candidate gene for lithium response involved in glutamatergic neurotransmission. One hundred five bipolar patients treated with lithium for at least 5 years were analyzed. The lithium response was assessed as excellent - no affective episodes during lithium treatment; partial - 50% reduction in the episode index; or no response - less than 50% reduction, no change or worsening in the episode index. Genotypes for the -200G/T, 366C/G and rs890G/T GRIN2B polymorphisms were established using the PCR-RFLP method. Genotype distributions were in Hardy-Weinberg equilibrium for all three polymorphisms. No association was found between the three polymorphisms studied and the treatment response to lithium. The authors conclude that polymorphisms of the GRIN2B gene did not show an association with the treatment response to lithium in bipolar patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19605943     DOI: 10.1016/s1734-1140(09)70085-4

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  8 in total

Review 1.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

Review 2.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

3.  Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors:  Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-01-31       Impact factor: 13.382

Review 4.  Response to treatment in bipolar disorder.

Authors:  Cristiana Cruceanu; Martin Alda; Guy Rouleau; Gustavo Turecki
Journal:  Curr Opin Psychiatry       Date:  2011-01       Impact factor: 4.741

Review 5.  Response to lithium in bipolar disorder: clinical and genetic findings.

Authors:  Janusz K Rybakowski
Journal:  ACS Chem Neurosci       Date:  2014-03-25       Impact factor: 4.418

Review 6.  Molecular actions and clinical pharmacogenetics of lithium therapy.

Authors:  Adem Can; Thomas G Schulze; Todd D Gould
Journal:  Pharmacol Biochem Behav       Date:  2014-02-15       Impact factor: 3.533

Review 7.  Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders.

Authors:  Rafael T de Sousa; Alexandre A Loch; André F Carvalho; André R Brunoni; Marie Reine Haddad; Ioline D Henter; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Neuropsychopharmacology       Date:  2016-08-11       Impact factor: 7.853

Review 8.  Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.

Authors:  Janusz K Rybakowski
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.